TVTX:NASDAQTravere Therapeutics, Inc. Analysis
Data as of 2026-08-31 - not real-time
$65.59
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Travere Therapeutics, Inc. is priced at $65.59 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it gained 18.2%. RSI sits at 61.4, which reads as approaching overbought, and MACD momentum is bullish. Price has been bracketed by support at $54.22 and resistance at $67.85.
Multiples put this in fair territory: 11.6 times earnings against the sector's 30.4. Analyst price targets sit 13.0% above the current price. Revenue is growing at 48.2% on a -7.3% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 42.7%, a beta of 1.53 and a maximum drawdown of 33.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 1 out of 10.
Multiples put this in fair territory: 11.6 times earnings against the sector's 30.4. Analyst price targets sit 13.0% above the current price. Revenue is growing at 48.2% on a -7.3% profit margin.
Risk comes out at 8 of a possible 10, a high reading. With 30-day volatility of 42.7%, a beta of 1.53 and a maximum drawdown of 33.5%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 1 out of 10.
Top Market Events
Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the...The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...SAN DIEGO, August 12, 2026--Travere Therapeutics, Inc.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 41.79
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 11.6 versus sector average of 30.4
- Trading above the 200-day average of 41.79
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 11.6 versus sector average of 30.4
- Negative profit margin of -7.3%
- Analyst targets imply +13.0% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth48.20%
Profit Margin-7.35%
P/E Ratio11.6
ROE-236.36%
ROA-3.73%
Debt/Equity2515.72
P/B Ratio61.4
Op. Cash Flow$92.7M
Free Cash Flow$-18254250
Industry P/E30.4
Technical Analysis
TrendBullish
RSI61.4
Support$54.22
Resistance$67.85
MA 20$63.55
MA 50$59.51
MA 200$41.79
MACDBullish
VolumeDecreasing
Fear & Greed Index94.32
Valuation
Fair Value$22.76
Target Price$74.14
Upside/Downside13.04%
GradeFair
TypeGrowth
Risk Assessment
Beta1.53
Volatility42.68%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.